AstraZeneca pays $560mm, plus potential $590mm in earn-outs, to buy Pearl Therapeutics
AstraZeneca PLC has paid $560mm up front to buy privately owned Pearl Therapeutics Inc., a company developing inhaled treatments for respiratory diseases. AZ could also pay up to $450mm in development and regulatory earn-outs, plus up to $140mm if specified cumulative sales thresholds are exceeded.
- Drug Delivery
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.